A Phase 3 interventional study of valsartan and pravastatin in Hypertension, sponsored by Fundación Lindavista del Corazón AC. Terminated. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-08-26.
Sponsored by Fundación Lindavista del Corazón AC · Phase 3, Interventional, and Treatment
Evaluate pleiotropic effects of simvastatin in hypertensive patients.
120 studies on the registry are indexed under Hypertrophy, Left Ventricular; 23 are open to participants now.
This study's enrollment of 12 is below the median of 120 across 69 interventional studies indexed under Hypertrophy, Left Ventricular.
Browse Hypertrophy, Left Ventricular studies →This is the only study on the registry with Fundación Lindavista del Corazón AC as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Participants who were administered Valsartan 80 mg plus paravastin 40 mg by mouth daily for one year. (Group A)
Drug: valsartan · Drug: pravastatin
Participants who were administered Valsartan 80 mg plus simvastatin 40 mg by mouth daily for one year. (Group B)
Drug: valsartan · Drug: simvastatin
Participants who were administered Valsartan 80 mg plus simvastatin 40 mg / ezetimibe 10 mg by mouth daily for one year. (Group C)
Drug: valsartan · Drug: ezetimibe (+) simvastatin
Participants who were administered Valsartan 80 mg by mouth daily for one year. (Group D)
Drug: valsartan
80 mg valsartan. Duration: 12 months. Tablets
Also known as: Diovan
40 mg pravastatin. Duration: 12 months. Tablets
Also known as: Pravacol
40 mg simvastatin. Duration: 12 months. Tablets
Also known as: Zocor, MK0733
ezetimibe (+) simvastatin 10/40 mg. Duration: 12 months. Tablets
Also known as: vytorin, MK0653A
Left Ventricular Hypertrophy Reduction With Statins in Hypertensive Patients
Left ventricular hypertrophy reduction was to be measured by echocardiography.
Time frame: 6 Month(s)
| Milestone | Valsartan 80 mg + Paravastin 40 mg | Valsartan 80 mg + Simvastatin 40 mg | Valsartan 80 mg + Simvastatin 40 mg / Ezetimibe 10 mg | Valsartan 80 mg |
|---|---|---|---|---|
| Started | 3 | 3 | 3 | 3 |
| Completed | 3 | 3 | 3 | 2 |
| Not completed | 0 | 0 | 0 | 1 |
Left ventricular hypertrophy reduction was to be measured by echocardiography.
No measurements were reported for this outcome.
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Valsartan 80 mg + Paravastin 40 mg | — | 0/3 (0%) | 0/3 (0%) |
| Valsartan 80 mg + Simvastatin 40 mg | — | 0/3 (0%) | 0/3 (0%) |
| Valsartan 80 mg + Simvastatin 40 mg / Ezetimibe 10 mg | — | 0/3 (0%) | 0/3 (0%) |
| Valsartan 80 mg | — | 0/2 (0%) | 0/2 (0%) |
| Age, Customized(participants) | Valsartan 80 mg + Paravastin 40 mg | Valsartan 80 mg + Simvastatin 40 mg | Valsartan 80 mg + Simvastatin 40 mg / Ezetimibe 10 mg | Valsartan 80 mg | Total |
|---|---|---|---|---|---|
| >18 years | 3 | 3 | 3 | 2 | 11 |
| Sex: Female, Male(Participants) | Valsartan 80 mg + Paravastin 40 mg | Valsartan 80 mg + Simvastatin 40 mg | Valsartan 80 mg + Simvastatin 40 mg / Ezetimibe 10 mg | Valsartan 80 mg | Total |
|---|---|---|---|---|---|
| Female | 2 | 2 | 2 | 2 | 8 |
| Male | 1 | 1 | 1 | 0 | 3 |
No study locations are listed for this record.
This study is terminated, as verified in Aug 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hypertrophy, Left Ventricular→